| Source: |
| Type: measurement |
| Bioavailability (usually in %) absorbed by the body. |
| 3582- | CUR, | PI, | Therapeutic and Preventive Effects of Piperine and its Combination with Curcumin as a Bioenhancer Against Aluminum-Induced Damage in the Astrocyte Cells |
| 3579- | CUR, | AgNPs, | Metal–Curcumin Complexes in Therapeutics: An Approach to Enhance Pharmacological Effects of Curcumin |
| - | Review, | NA, | NA |
| 3578- | CUR, | SIL, | Curcumin, but not its degradation products, in combination with silibinin is primarily responsible for the inhibition of colon cancer cell proliferation |
| - | in-vitro, | CRC, | DLD1 |
| 3577- | CUR, | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study |
| - | Trial, | AD, | NA |
| 3576- | CUR, | Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer's Disease |
| - | Review, | AD, | NA |
| 3574- | CUR, | The effect of curcumin (turmeric) on Alzheimer's disease: An overview |
| - | Review, | AD, | NA |
| 4829- | CUR, | Dual Action of Curcumin as an Anti- and Pro-Oxidant from a Biophysical Perspective |
| - | Review, | Var, | NA |
| 4826- | CUR, | The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management |
| - | Review, | Var, | NA |
| 4655- | CUR, | Inhibition of Cancer Stem-like Cells by Curcumin and Other Polyphenol Derivatives in MDA-MB-231 TNBC Cells |
| - | in-vitro, | BC, | NA |
| 4651- | CUR, | Targeting cancer stem cells by curcumin and clinical applications |
| - | Review, | Var, | NA |
| 4672- | CUR, | An old spice with new tricks: Curcumin targets adenoma and colorectal cancer stem-like cells associated with poor survival outcomes |
| - | vitro+vivo, | CRC, | HCT116 |
| 2305- | CUR, | Mitochondrial targeting nano-curcumin for attenuation on PKM2 and FASN |
| - | in-vitro, | BC, | MCF7 |
| 2308- | CUR, | Counteracting Action of Curcumin on High Glucose-Induced Chemoresistance in Hepatic Carcinoma Cells |
| - | in-vitro, | Liver, | HepG2 |
| 2654- | CUR, | Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence |
| - | Review, | Var, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2817- | CUR, | Neuroprotection by curcumin: A review on brain delivery strategies |
| - | Review, | Nor, | NA |
| 2809- | CUR, | Comparative absorption of curcumin formulations |
| - | in-vivo, | Nor, | NA |
| 2814- | CUR, | Curcumin in Cancer and Inflammation: An In-Depth Exploration of Molecular Interactions, Therapeutic Potentials, and the Role in Disease Management |
| - | Review, | Var, | NA |
| 2816- | CUR, | NEUROPROTECTIVE EFFECTS OF CURCUMIN |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 6252- | Cyc, | Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance |
| - | Review, | Var, | NA |
| 6686- | DAP, | Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 6591- | DAS, | Dasatinib in solid tumors |
| - | Review, | Var, | NA |
| 6590- | DAS, | Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells |
| - | in-vitro, | Pca, | NA |
| 6683- | DCA, | Dichloroacetate for Cancer Treatment: Some Facts and Many Doubts |
| - | Review, | Var, | NA |
| 6681- | DCA, | Dichloroacetate (DCA) in Cancer Care |
| 6671- | Deg, | A Novel Derivative of the Natural Agent Deguelin for Cancer Chemoprevention and Therapy |
| - | in-vitro, | Nor, | BEAS-2B | - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | H460 |
| 6670- | Deg, | Pharmacokinetics of deguelin, a cancer chemopreventive agent in rats |
| - | in-vivo, | Nor, | NA |
| 6702- | DFC, | Diclofenac |
| - | Review, | Nor, | NA |
| 6705- | DFC, | Development and Challenges of Diclofenac-Based Novel Therapeutics: Targeting Cancer and Complex Diseases |
| - | Review, | Var, | NA |
| 6694- | DFC, | Repurposing Drugs in Oncology (ReDO)—diclofenac as an anti-cancer agent |
| - | Review, | Var, | NA |
| 6288- | DL, | From Citrus to Clinic: Limonene’s Journey Through Preclinical Research, Clinical Trials, and Formulation Innovations |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 6281- | DL, | Applications of Limonene in Neoplasms and Non-Neoplastic Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | Diabetic, | NA |
| 6363- | DRE, | Therapeutic Potential of Dandelion (Taraxacum officinale) Root Extract in Colon Cancer: A Comprehensive Review |
| - | in-vitro, | CRC, | NA |
| 4914- | DSF, | immuno, | Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies |
| - | Review, | Var, | NA |
| 5011- | DSF, | Cu, | Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens |
| - | Review, | Var, | NA |
| 5012- | DSF, | Cu, | Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems |
| 4832- | EA, | Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid |
| 6801- | EA, | A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury |
| - | vitro+vivo, | BC, | 4T1 |
| 1605- | EA, | Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence |
| - | Review, | Var, | NA |
| 1608- | EA, | Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HUVECs |
| 1611- | EA, | Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues |
| - | in-vitro, | Mal, | NA |
| 1615- | EA, | Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers |
| - | Human, | Nor, | NA |
| 6604- | Ech, | Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion |
| - | Human, | Nor, | NA |
| 7222- | EGb 761, | Ginkgo biloba extract EGb 761® in the symptomatic treatment of mild-to-moderate dementia: a profile of its use |
| - | Review, | AD, | NA |
| 3201- | EGCG, | Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential |
| - | Review, | NA, | NA |
| 3593- | EGCG, | Epigallocatechin Gallate (EGCG) |
| - | Review, | AD, | NA |
| 6780- | EGCG, | The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review |
| - | Review, | AD, | NA |
| 6779- | EGCG, | Effectiveness of epigallocatechin gallate nanoparticles on the in-vivo treatment of Alzheimer's disease in a rat/mouse model: a systematic review |
| - | Review, | AD, | NA |
| 6783- | EGCG, | Absorption, metabolism, bioactivity, and biotransformation of epigallocatechin gallate |
| - | Review, | Nor, | NA |
| 6782- | EGCG, | Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability |
| - | Human, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:792 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid